BioMarin Pharmaceutical (NASDAQ: BMRN) is engaged in the development and commercialization of pioneering biopharmaceuticals for serious diseases and medical conditions. BioMarin’s product portfolio includes four approved products and many clinical and pre-clinical product candidates. The company’s approved products include Naglazyme, wholly developed and commercialized by BioMarin; Aldurazyme, developed through a 50/50 joint venture with Genzyme Corporation; Kuvan Tablets, developed in partnership with Merck Serono; and Firdapse, which has received approval from the European Commission. For more information, visit the company’s Web site at www.bmrn.com
William Blair & Company is a global investment banking and asset management firm committed to building enduring relationships with clients and providing expertise and solutions to meet their evolving needs. An independent and employee-owned firm, William Blair is based in Chicago, and has office locations in 10 cities, including London, New York, Shanghai, and Zurich. For more information on William Blair & Company, visit www.williamblair.com
Let us hear your thoughts below: